Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab Versus Placebo in Subjects With High Risk Invasive Urothelial Carcinoma (CheckMate 274: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 274)

Next Previous
Search
Trial Profile

A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab Versus Placebo in Subjects With High Risk Invasive Urothelial Carcinoma (CheckMate 274: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 274)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Bladder cancer; Carcinoma; Renal cancer; Ureteral neoplasms; Urogenital cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CheckMate 274
  • Sponsors Bristol-Myers Squibb

Most Recent Events

  • 27 Jan 2024 Results of an analysis employed mixture cure models assessing underlying cure fraction among high-risk MIUC patients following radical resection in this trial presented at the 2024 Genitourinary Cancers Symposium
  • 17 Jan 2024 According to a Bristol-Myers Squibb media release, analyses of disease-free survival from this study will be presented in a late-breaking oral presentation at the American Society of Clinical Oncology 2024 Genitourinary Cancers Symposium (ASCO GU) to be held from January 25-27 in San Francisco, California.
  • 02 Jan 2024 Planned End Date changed from 15 May 2027 to 27 May 2027.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top